Amgen's earnings call highlights strong Q3 performance, exceeding expectations with raised guidance for 2008 revenue and EPS.  Management expressed confidence in the company's pipeline, particularly the denosumab program, and emphasized their ability to adapt to challenging market conditions.  While some concerns about Aranesp sales and possible biosimilar competition were acknowledged, the overall tone suggests a positive outlook for the next 1-2 weeks, likely driving stock price appreciation.
[1]
